Drug intelligence / Profile preview

CB-NK Exosome

Development stage: Unknown
Lead developer: Shining Biotech
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

CB-NK Exosome is a research and manufacturing platform tool developed by Shining Biotech, consisting of extracellular vesicles (exosomes) derived from cord blood-derived natural killer (NK) cells. These exosomes are designed to harness the innate cytotoxic and immunomodulatory properties of NK cells, potentially offering a cell-free alternative to NK cell therapies. The platform is utilized for R&D and manufacturing purposes rather than as a specific clinical-stage therapeutic candidate.

Other names: cord blood-derived NK-cell exosome

Targets

TNFRSF10A (Death receptor 4)NECTIN2 (Nectin cell adhesion molecule 2)FASN (Fatty acid synthase)PVR

Beyond the preview

Go deeper on CB-NK Exosome.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CB-NK Exosome.

Explore the full profile